UK Women’s Views of the Concepts of Personalised Breast Cancer Risk Assessment and Risk-Stratified Breast Screening: A Qualitative Interview Study
Abstract
:Simple Summary
Abstract
1. Introduction
- Explore women’s understanding and experience of breast screening in the context of their responses to PRA and RSBS;
- Gain insight to women’s understanding of and prospective willingness to undergo multifactorial PRA;
- Explore prospective acceptability of possible RSBS scenarios in which screening frequency, age-range of eligibility and number of risk groups might vary.
- Assess how risk-management options, such as lifestyle change and chemoprevention, are seen in the context of RSBS scenarios.
2. Materials and Methods
2.1. Participants
2.2. Procedure
2.3. Data Analysis
3. Results
3.1. Participant Characteristics
3.2. Thematic Framework
3.2.1. Risk Perceptions and Acceptability of Personalised Risk Assessment
Perceived Risk
Acceptability of Providing Risk Information
“I think that’s so routine, isn’t it? You’re asked it on every questionnaire, “Do you smoke, drink?” (4: Regular, 50 years).
“I think that would worry me, if it came back that there were enough little pointers to the direction that I could develop breast cancer …. Oh, I don’t know the answer to that one” (16: Regular, 67 years).
“Well, it would still be a mammogram, wouldn’t it? For all intents and purposes, it’s getting involved in the system” (9: Non-attender, 51 years).
Understanding of PRA
“These days everything is so tailored and personalised and we’re in that kind of society now…we can’t have that standard one size fits all model anymore” (11: Pre-eligible, 46 years).
“And then they can go on from that to decide whether you need more or less breast screening and so it’s in everybody’s interests” (21: Regular, 51 years).
“So, if I had my risk assessment done today. And then next week I’m suffering terribly with hot flushes…and suddenly take HRT, would that be flagged to the risk-assessment people?” (15: Regular, 59 years).
Willingness to Receive Risk Feedback
“There’s nothing worse than sort of like having that wondering. At least if you know… you can deal with it, however hard that might be” (21: Regular, 51 years).
“Because then if you find something, and you think ‘I’m in that 10% of really low, look what I’m finding’… so they’re [health professionals] are going to think what’s changed. What’s happened, what’s she doing differently? So, they can look at the information they hold on me to see why this change has occurred?” (20: Regular, 52 years).
“Well, there’s a risk in knowing itself … because of the anxiety from it. But you can’t just plod along thinking everything’s fine… it’s just being responsible for your health in a way …. It’s just something that you’d have to do whether it’s pleasant or unpleasant” (18: Pre-eligible, 40 years)
“… if you’re given a risk profile and it’s high and you then realise you’re at a stage when you’re quite terminal, I don’t know whether I’d really actually want to know or whether I’d just want to live my life without knowing if nothing can be done” (4: Regular, 50 years).
“I mean this is going to be a mandatory kind of thing. You’ll have to go to the doctor’s to give this information, and it’ll just be done, as a matter of fact, in the future” (6: Regular, 56 years).
3.2.2. Ways of Responding to RSBS Scenarios
A Typology: (1) ‘Overall Acceptors’; (2) ‘More Is Better’; (3) ‘Screening Sceptics’
Age-Range of Screening Eligibility
“I think … you would want to have those additional checks and those earlier checks as well, because obviously that’s going to be a concern if you’re high-risk and you’re going to want to do something about it, so I think yes, definitely” (18: Pre-eligible, 40 years).
“I mean, it’s always down to cost anyway. So, if they can’t increase it because of the cost, then I do think that the age-range is acceptable” (22: Regular, 60 years).
“As long as it’s backed up by heaps of scientific data and everyone agrees that 55 to 65 is when everybody should really be checked, because that’s a scare time, but as long as it all stacks up then it makes perfect sense to me” (5: Regular, 59 years).
“I think that even though I am low risk, my social circle, or the women that I’m in touch with or the media, all of those things, because breast cancer is such a common thing now, I would worry that… because my risk profile has given me a low-risk, [screening from] 55 seems too late” (4: Regular, 50 years).
Screening Frequency
“I mean, it’s still bad … but you can do something about it... it’s not ever going to go… but if there’s a lifeline thrown at you like a lifestyle change and maybe tablets then yes, I would take that “ (15: Regular, 59 years).
“It certainly seems a lot, but … if you fall into that category, I think that you’d want to know that everything was being done. So, six months does seem a little excessive to me. But, you know, if it just saves one woman, then to me it’s worth the risk” (23: Regular, 60 years).
“I would imagine as soon as you’ve gone for one, you’re pretty much on top of another one” (23: Regular, 60 years).
“That would be a difficult adjustment to make. I’d have to be told “This is going to save your life really”, to take that on board. It would also feel like a bit of a shadow… It’s sort of not a death sentence, but you know what I mean? … it would be hard not to think negative things about that” (17: Occasional, 61 years).
“If I was found not to be at great risk, it would put me out of my misery having to go for it because it’s not nice” (16: Regular, 67 years).
“I suppose it’s about making sure, even in the low-risk bracket, you know what things you could be doing yourself to monitor things as well” (14: Pre-eligible, 47 years).
“After the first year of the screen I will worry … [and will have] to wait another four years. So that means I have to check my body more frequently myself” (12: Regular, 68 years).
“There should be maybe an option that even if you are in a low risk … you should be given the opportunity to have them more frequently” (2: Pre-eligible, 41 years).
No Screening—Very Low-Risk
“So, if the health professional reassured me, I would probably be relieved …if you’ve gone through everything from the risk assessments and highlighted all the positives and negatives, and if the negatives are going to outweigh the positives, I would then be persuaded not to have the screening” (11: Pre-eligible, 46 years).
3.2.3. Influence of ‘Ladder of Risk’ on Responses to RSBS Scenarios
“… the human psyche does weigh things up and you look at who’s above you and below you … placing yourself on a sort of scale” (17: Occasional, 51 years).
“Yes, now, compared to the high-risk, it [moderate risk 12–18-month intervals] seems more manageable” (11: Pre-eligible, 46 years).
“I think having seen… that there are people a lot more at risk than you, this is okay” (22: Regular, 60 years).
“seeing … there’s a couple of levels above me, I’ve nothing to worry about. It might give people a false sense of security” (16: Regular, 67 years).
“I’d be thinking, well, there’s people that are at higher risk that need to be getting that extra level of care, and I don’t need it” (21: Occasional, 51 years).
3.2.4. Concerns and Conditions of Acceptability
Information Support
“If things were explained properly, then I think the majority of women will actually go for it … there’s lack of information even now, isn’t there? (21: Occasional, 51 years).
Breast Awareness Support
“I would be happy to come out of a risk assessment and deemed to be very low-risk, but I’m not convinced with my own approach to self-checks” (18: Pre-eligible, 40 years).
“I would just want to see much more information about how you can examine your breasts or go to a nurse or doctor to just have them feel your breasts without going to a mammogram if you’re anxious …” (17: Occasional, 61 years).
Integration of PRA and RSBS
“I assume [PRA] is an ongoing thing isn’t it? Because down the line they will have, once they’ve done the screening, more results to see how accurate it can be and how it can be beneficial” (6: Regular, 56 years).
3.2.5. Perceived Effectiveness: RSBS vs. Current NHSBSP
“It really makes sense with all that added information and you can only get better treatment… the old system seems a bit dated” (11: Pre-eligible, 46 years).
“I don’t see where those high-risk groups, especially, because that’s where the focus needs to be, they’re just flowing through at the same rate and that could be where there’s a lot of issues” (18: Pre-eligible, 40 years).
“… you know, thousands and thousands of women have been going and loving it for years and years. That’s kind of reassuring from that aspect” (11: Pre-eligible, 46 years).
4. Discussion
Strengths and Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Curtis, C.; Shah, S.P.; Chin, S.F.; Turashvili, G.; Rueda, O.M.; Dunning, M.J.; Speed, D.; Lynch, A.G.; Samarajiwa, S.; Yuan, Y.; et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012, 486, 346–532. [Google Scholar] [CrossRef]
- Darabi, H.; Czene, K.; Zhao, W.; Liu, J.; Hall, P.; Humphreys, K. Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res. 2012, 14, R25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, A.; Mavaddat, N.; Wilcox, A.N.; Cunningham, A.P.; Carver, T.; Hartley, S.; de Villiers, C.B.; Izquierdo, A.; Simard, J.; Schmidt, M.K.; et al. BOADICEA: A comprehensive breast cancer risk model incorporating genetic and nongenetic risk factors. Genet. Med. 2019, 21, 1708–1718. [Google Scholar] [CrossRef] [Green Version]
- Pashayan, N.; Antoniou, A.C.; Ivanus, U.; Esserman, L.J.; Easton, D.F.; French, D.; Sroczynski, G.; Hall, P.; Cuzick, J.; Evans, D.G.; et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat. Rev. Clin. Oncol. 2020, 17, 687–705. [Google Scholar] [CrossRef] [PubMed]
- Mühlberger, N.; Sroczynski, G.; Gogollari, A.; Jahn, B.; Pashayan, N.; Steyerberg, E.; Widschwendter, M.; Siebert, U. Cost effectiveness of breast cancer screening and prevention: A systematic review with a focus on risk-adapted strategies. Eur. J. Health Econ. 2021, 1–34. [Google Scholar] [CrossRef]
- Pashayan, N.; Morris, S.; Gilbert, F.; Pharoah, P.D. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model. JAMA Oncol. 2018, 4, 1504–1510. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sankatsing, V.; van Revesteyn, N.; Heijndisjk, E.; Broeders, M.; de Koning, H. Risk stratification in breast cancer screening: Cost-effectiveness and harm-benefit ratios for low-risk and high-risk women. Int. J. Cancer 2020, 147, 3059–3067. [Google Scholar] [CrossRef] [PubMed]
- Vilaprinyo, E.; Forne, C.; Carles, M.; Sala, M.; Pla, R.; Castells, X.; Domingo, L.; Rue, M.; Interval Cancer (INCA) Study Group. Cost-Effectiveness and Harm-Benefit Analyses of Risk-Based Screening Strategies for Breast Cancer. PLoS ONE 2014, 9, e86858. [Google Scholar] [CrossRef] [Green Version]
- Brooks, J.D.; Nabi, H.H.; Andrulis, I.L.; Antoniou, A.C.; Chiquette, J.; Després, P.; Devilee, P.; Dorval, M.; Droit, A.; Easton, D.F.; et al. Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). J. Pers. Med. 2021, 11, 511. [Google Scholar] [CrossRef] [PubMed]
- Dent, T.; Jbilou, J.; Rafi, I.; Segnan, N.; Törnberg, S.; Chowdhury, S.; Hall, A.; Lyratzopoulos, G.; Eeles, R.; Eccles, D.; et al. Stratified Cancer Screening: The Practicalities of Implementation. Public Health Genom. 2013, 16, 94–99. [Google Scholar] [CrossRef]
- Koitsalu, M.; Sprangers, M.; Eklund, M.; Czene, K.; Hall, P.; Grönberg, H.; Brandberg, Y. Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer. Acta Oncol. 2015, 55, 45–51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mbuya Bienge, C.; Pashayan, N.; Brooks, J.D.; Dorval, M.; Chiquette, J.; Eloy, L.; Turgeon, A.; Lambert-Côté, L.; Paquette, J.S.; Lévesque, E.; et al. Women’s Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada. J. Pers. Med. 2021, 11, 95. [Google Scholar] [CrossRef] [PubMed]
- Rainey, L.; van der Waal, D.; Broeders, M.J. Dutch women’s intended participation in a risk-based breast cancer screening and prevention programme: A survey study identifying preferences, facilitators and barriers. BMC Cancer 2020, 20, 965. [Google Scholar] [CrossRef]
- Ghanouni, A.; Sanderson, S.C.; Pashayan, N.; Renzi, C.; von Wagner, C.; Waller, J. Attitudes towards risk-stratified breast cancer screening among women in England: A cross-sectional survey. J. Med. Screen. 2020, 27, 138–145. [Google Scholar] [CrossRef] [Green Version]
- Evans, D.G.; Donnelly, L.S.; Harkness, E.F.; Astley, S.M.; Stavrinos, P.; Dawe, S.; Watterson, D.; Fox, L.; Sergeant, J.C.; Ingham, S.; et al. Breast cancer risk feedback to women in the UK NHS breast screening population. Br. J. Cancer 2016, 114, 1045–1052. [Google Scholar] [CrossRef] [PubMed]
- Henneman, L.; Timmermans, D.R.; Bouwman, C.M.; Cornel, M.C.; Meijers-Heijboer, H. “A low risk is still a risk”: Exploring women’s attitudes towards genetic testing for breast cancer susceptibility in order to target disease prevention. Public Health Genom. 2011, 14, 238–247. [Google Scholar] [CrossRef] [PubMed]
- He, X.; Schifferdecker, K.E.; Ozanne, E.; Tosteson, A.; Woloshin, S.; Schwartz, L.M. How Do Women View Risk-Based Mammography Screening? A Qualitative Study. J. Gen. Intern Med. 2018, 33, 1905–1912. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lippey, J.; Keogh LA Bruce Mann, G.; Campbell, I.G.; Forrest, L.E. “A natural progression”: Australian women’s attitudes about an individualized breast screening model. Cancer Prev. Res. 2019, 12, 383–390. [Google Scholar] [CrossRef] [Green Version]
- Rainey, L.; Jervaeus, A.; Donnelly, L.S.; Evans, D.G.; Hammarström, M.; Hall, P.; Wengström, Y.; Broeders, M.J.; van der Waal, D. Women’s perceptions of personalized risk-based breast cancer screening and prevention: An international focus group study. Psycho-Oncol. 2019, 28, 1056–1062. [Google Scholar] [CrossRef] [Green Version]
- Meisel, S.F.; Pashayan, N.; Rahman, B.; Side, L.; Fraser, L.; Gessler, S.; Lanceley, A.; Wardle, J. Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK. Breast 2015, 24, 237–241. [Google Scholar] [CrossRef] [Green Version]
- Mathioudakis, A.G.; Salakari, M.; Pylkkanen, L.; Saz-Parkinson, Z.; Bramesfeld, A.; Deandrea, S.; Lerda, D.; Neamtiu, L.; Pardo-Hernandez, H.; Solà, I.; et al. Systematic review on women’s values and preferences concerning breast cancer screening and diagnostic services. Psycho-Oncol. 2019, 28, 939–947. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lerman, C.; Trock, B.; Rimer Jespon, C.; Brody, D.; Boyce, A. Psychological side effects of breast cancer screening. Health Psychol. 1991, 10, 259–267. [Google Scholar] [CrossRef]
- Rubin, H.J.; Rubin, I.S. The responsive interview as an extended conversation. In Qualitative Interviewing: The Art of Hearing Data, 2nd ed.; Rubin, H.J., Rubin, I.S., Eds.; SAGE Publications: Thousand Oaks, CA, USA, 2012; pp. 108–128. Available online: https://www.doi.org/10.4135/9781452226651 (accessed on 9 September 2021).
- Spencer, L.; Ritchie, J. Analysis in Practice. In Qualitative Research Practice: A Guide for Social Science Students and Researchers, 2nd ed.; Ritchie, J., Lewis, J., Eds.; SAGE Publications: Los Angeles, CA, USA, 2014; pp. 295–343. [Google Scholar]
- Braun, V.; Clarke, V. One size fits all? What counts as quality practice in (reflexive) thematic analysis? Qual. Res. Psychol. 2020, 18, 328–352. [Google Scholar] [CrossRef]
- McWilliams, L.; Woof, V.G.; Donnelly, L.S.; Howell, A.; Evans, D.G.; French, D. Extending screening intervals for women at low risk of breast cancer: Do they find it acceptable? BMC Cancer 2021, 21, 637. [Google Scholar] [CrossRef]
- French, D.P.; Astley, S.; Astley, S.; Brentnall, A.R.; Cuzick, J.; Dobrashian, R.; Duffy, S.W.; Gorman, L.S.; Gorman, L.S.; Harkness, E.F.; et al. What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT4349429). BMC Cancer 2020, 20, 579. [Google Scholar]
- Ng, K.-H.; Lau, S. Vision 20/20: Mammographic breast density and its clinical applications. Med. Phys. 2015, 42, 7059–7077. [Google Scholar] [CrossRef]
- Vachon, C.M.; Brandt, K.R.; Ghosh, K.; Scott, C.G.; Maloney, S.D.; Carston, M.J.; Pankratz, V.S.; Sellers, T.A. Mammographic Breast Density as a General Marker of Breast Cancer Risk. Cancer Epidemiol. Prev. Biomarkers 2007, 16, 43–49. [Google Scholar] [CrossRef] [Green Version]
- Wegwarth, O.; Pashayan, N.; Widschwendter, M.; Rebitschek, F.G. Women’s perception, attitudes, and intended behavior towards predictive epigenetic risk testing for female cancers in 5 European countries: A cross-sectional online survey. BMC Public Health 2019, 19, 667. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schuurman, A.; van der Kolk, D.; Verkerk, M.A.; Birnie, E.; Ranchor, A.V.; Plantinga, M.; van Langen, I.M. Maximising the efficiency of clinical screening programmes: Balancing predictive genetic testing with a right not to know. Eur. J. Hum. Genet. 2015, 23, 1124–1128. [Google Scholar] [CrossRef] [PubMed]
- Woof, V.G.; Ruane, H.; French, D.P.; Ulph, F.; Qureshi, N.; Khan, N.; Evans, D.G.; Donnelly, L.S. The introduction of risk stratified screening into the NHS breast screening Programme: Views from British-Pakistani women. BMC Cancer 2020, 20, 452. [Google Scholar] [CrossRef]
- Kahneman, D.; Knetsch, J.L.; Thaler, R.H. Anomalies: The Endowment Effect, Loss Aversion, and Status Quo Bias. J. Econ. Perspect. 1991, 5, 193–206. [Google Scholar] [CrossRef] [Green Version]
- Howell, A.; Anderson, A.S.; Clarke, R.B.; Duffy, S.W.; Evans, G.; Garcia-Closas, M.; Gescher, A.J.; Key, T.J.; Saxton, J.M.; Harvie, M.N. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014, 16, 446. [Google Scholar] [CrossRef] [PubMed]
- Ghanouni, A.; Meisel, S.F.; Renzi, C.; Wardle, J.; Waller, J. Survey of public definitions of the term “overdiagnosis” in the UK. BMJ Open 2016, 6, e010723. [Google Scholar] [CrossRef]
- Woloshin, S.; Schwartz, L.M.; Black, W.C.; Kramer, B.S. Cancer screening campaigns—Getting past uninformative persuasion. N. Engl. J. Med. 2012, 367, 1677–1679. [Google Scholar] [CrossRef] [PubMed]
- Smith, D.; Thomson, K.; Bambra, C.; Todd, A. The breast cancer paradox: A systematic review of the association between area-level deprivation and breast cancer screening uptake in Europe. Cancer Epidemiol. 2019, 60, 77–85. [Google Scholar] [CrossRef]
- Blouin-Bougie, J.; Amara, N.; Simard, J. Toward a population-based breast cancer risk stratification approach? The needs and concerns of healthcare providers. J. Pers. Med. 2021, 11, 540. [Google Scholar] [CrossRef] [PubMed]
- McWilliams, L.; Woof, V.G.; Donnelly, L.S.; Howell, A.; Gareth Evans, D.; French, D.P. Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholders’ views on a low-risk breast screening pathway. BMC Cancer 2020, 20, 680. [Google Scholar] [CrossRef]
- Rainey, L.; van der Waal, D.; Donnelly, L.S.; Gareth Evans, D.; Wengström, Y.; Broeders, M. Women’s decision-making regarding risk-stratified breast cancer screening and prevention from the perspective of international healthcare professionals. PLoS ONE 2018, 13, e0197772. [Google Scholar] [CrossRef] [Green Version]
Characteristic | All (n = 25) | 1 Overall Acceptors (n = 10) | 2 More Is Better (n = 9) | 3 Screening Sceptics (n = 6) |
---|---|---|---|---|
Age range (mean, SD) | 40–68 (54.96 ± 8.64) | 40–68 (53.30 ± 9.62) | 41–68 (53.11 ± 8.57) | 52–65 (60.5 ± 5.09) |
Age categories | ||||
40–49 | 7 | 3 | 4 | - |
50–59 | 9 | 4 | 3 | 2 |
60–70 | 9 | 2 | 3 | 4 |
Breast screening experience | ||||
Pre-eligible | 7 | 4 | 3 | - |
Regular attender | 7 | 3 | 4 | - |
Occasional attender | 6 | 3 | 2 | 1 |
Non-attender | 5 | - | - | 5 |
Occupational social grade | ||||
AB-C1 (managerial/professional) | 13 | 4 | 5 | 4 |
C2-DE (manual/semi-skilled) | 12 | 6 | 4 | 2 |
Educational attainment | ||||
No qualifications | 1 | - | 1 | - |
GCE/O’level | 4 | - | 4 | - |
A’level or equivalent | 6 | 2 | 3 | - |
University degree | 6 | 4 | - | 2 |
Masters or higher | 5 | 1 | 1 | 3 |
Other (e.g., City & Guilds) | 3 | 3 | - | 1 |
Ethnicity | ||||
White British | 19 | 9 | 5 | 5 |
Black Caribbean | 2 | - | 1 | 1 |
Asian | 4 | 1 | 3 | |
Perceived risk of breast cancer | ||||
Much higher | - | - | - | - |
A little higher | 4 | 2 | 1 | 1 |
About the same | 14 | 6 | 8 | 1 |
A little lower | 4 | 1 | - | 3 |
Much lower | 3 | 1 | - | 1 |
Breast cancer worry (intensity) | ||||
Extremely | - | - | - | - |
Quite a bit | 10 | 4 | 6 | - |
Slightly | 10 | 4 | 3 | 3 |
Not at all | 5 | 2 | - | 3 |
Breast cancer worry (frequency) | ||||
Very often | - | - | - | - |
Often | 2 | 1 | 1 | - |
Sometimes | 10 | 6 | 4 | 1 |
Occasional | 10 | 2 | 4 | 3 |
Never | 3 | 1 | - | 2 |
Theme | Subtheme |
---|---|
Risk perceptions and acceptability of personalised risk assessment (PRA) |
|
Ways of responding to risk- stratified breast screening (RSBS) scenarios |
|
Influence of ‘ladder of risk’ on responses to RSBS scenarios | |
Concerns and conditions of acceptability |
|
Perceived effectiveness: RSBS vs. current NHSBSP |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kelley-Jones, C.; Scott, S.; Waller, J. UK Women’s Views of the Concepts of Personalised Breast Cancer Risk Assessment and Risk-Stratified Breast Screening: A Qualitative Interview Study. Cancers 2021, 13, 5813. https://doi.org/10.3390/cancers13225813
Kelley-Jones C, Scott S, Waller J. UK Women’s Views of the Concepts of Personalised Breast Cancer Risk Assessment and Risk-Stratified Breast Screening: A Qualitative Interview Study. Cancers. 2021; 13(22):5813. https://doi.org/10.3390/cancers13225813
Chicago/Turabian StyleKelley-Jones, Charlotte, Suzanne Scott, and Jo Waller. 2021. "UK Women’s Views of the Concepts of Personalised Breast Cancer Risk Assessment and Risk-Stratified Breast Screening: A Qualitative Interview Study" Cancers 13, no. 22: 5813. https://doi.org/10.3390/cancers13225813
APA StyleKelley-Jones, C., Scott, S., & Waller, J. (2021). UK Women’s Views of the Concepts of Personalised Breast Cancer Risk Assessment and Risk-Stratified Breast Screening: A Qualitative Interview Study. Cancers, 13(22), 5813. https://doi.org/10.3390/cancers13225813